Data were presented on the safety and tolerance studies for 3TC, another AZT/ddI/ddC-like antiretroviral drug being developed by the Glaxo pharmaceutical company. While offering no promise of being a real breakthrough in therapy, the studies indicate good reason for believing this may turn out to be the least toxic of its class. Indeed, early tests in people reveal NO significant toxic side effects at effective doses. More extensive clinical trials are expected to begin early in 1993.
Even smaller and earlier safety and tolerance studies were also presented on different classes of antiviral drugs, particularly the tat and protease inhibitors. These indicated mostly that trials are continuing without significant new evidence so far of either discouraging or exciting nature.
921101
BA921108
AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.
This information is designed to support, not replace, the relationship that exists between you and your doctor.